As of August 14, 2014, Mallinckrodt ARD Inc. was acquired by Mallinckrodt plc. Mallinckrodt ARD Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Acthar Gel, an injectable drug to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; as exacerbation or maintenance therapy in various cases of systemic lupus erythematosus and systemic dermatomyositis; and as adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. Its H.P. Acthar Gel is also used for the treatment of acute exacerbations of multiple sclerosis in adults; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company sells its product primarily to specialty pharmacies. Mallinckrodt ARD Inc. was formerly known as Questcor Pharmaceuticals, Inc. and changed its name to Mallinckrodt ARD Inc. in July 2015. The company was founded in 1990 and is based in Bedminster, New Jersey. On August 28, 2023, Mallinckrodt ARD LLC filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.